Literature DB >> 23849040

PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats.

N Snelder1, B A Ploeger, O Luttringer, D F Rigel, R L Webb, D Feldman, F Fu, M Beil, L Jin, D R Stanski, M Danhof.   

Abstract

BACKGROUND AND
PURPOSE: The homeostatic control of arterial BP is well understood with changes in BP resulting from changes in cardiac output (CO) and/or total peripheral resistance (TPR). A mechanism-based and quantitative analysis of drug effects on this interrelationship could provide a basis for the prediction of drug effects on BP. Hence, we aimed to develop a mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model in rats that could be used to characterize the effects of cardiovascular drugs with different mechanisms of action (MoA) on the interrelationship between BP, CO and TPR. EXPERIMENTAL APPROACH: The cardiovascular effects of six drugs with diverse MoA, (amlodipine, fasudil, enalapril, propranolol, hydrochlorothiazide and prazosin) were characterized in spontaneously hypertensive rats. The rats were chronically instrumented with ascending aortic flow probes and/or aortic catheters/radiotransmitters for continuous recording of CO and/or BP. Data were analysed in conjunction with independent information on the time course of drug concentration using a mechanism-based PKPD modelling approach. KEY
RESULTS: By simultaneous analysis of the effects of six different compounds, the dynamics of the interrelationship between BP, CO and TPR were quantified. System-specific parameters could be distinguished from drug-specific parameters indicating that the model developed is drug-independent. CONCLUSIONS AND IMPLICATIONS: A system-specific model characterizing the interrelationship between BP, CO and TPR was obtained, which can be used to quantify and predict the cardiovascular effects of a drug and to elucidate the MoA for novel compounds. Ultimately, the proposed PKPD model could be used to predict the effects of a particular drug on BP in humans based on preclinical data.
© 2013 The Authors. British Journal of Pharmacology © 2013 The British Pharmacological Society.

Entities:  

Keywords:  BP; CVS; NONMEM; PKPD model; cardiac output; drug effects; mechanism-based; peripheral resistance; rats

Mesh:

Substances:

Year:  2013        PMID: 23849040      PMCID: PMC3724108          DOI: 10.1111/bph.12190

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  The fourth dimension of life: fractal geometry and allometric scaling of organisms.

Authors:  G B West; J H Brown; B J Enquist
Journal:  Science       Date:  1999-06-04       Impact factor: 47.728

Review 2.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

Authors:  Meindert Danhof; Joost de Jongh; Elizabeth C M De Lange; Oscar Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 3.  Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

Authors:  Meindert Danhof; Elizabeth C M de Lange; Oscar E Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Trends Pharmacol Sci       Date:  2008-03-18       Impact factor: 14.819

4.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte Op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina; Alex Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Christian Funck-Brentano; Gerasimos Filippatos; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jóse Luis Zamorano; Attila Altiner; Enzo Bonora; Paul N Durrington; Robert Fagard; Simona Giampaoli; Harry Hemingway; Jan Hakansson; Sverre Erik Kjeldsen; Mogens Lytken Larsen; Giuseppe Mancia; Athanasios J Manolis; Kristina Orth-Gomer; Terje Pedersen; Mike Rayner; Lars Ryden; Mario Sammut; Neil Schneiderman; Anton F Stalenhoef; Lale Tokgözoglu; Olov Wiklund; Antonis Zampelas
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2007-09

5.  Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.

Authors:  Edward Perez-Reyes; Amy L Van Deusen; Iuliia Vitko
Journal:  J Pharmacol Exp Ther       Date:  2008-10-30       Impact factor: 4.030

Review 6.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.

Authors:  A Sharma; W J Jusko
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

7.  Characterization of four basic models of indirect pharmacodynamic responses.

Authors:  A Sharma; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

Review 8.  Cardiac effects of calcium antagonists in systemic hypertension.

Authors:  L Michalewicz; F H Messerli
Journal:  Am J Cardiol       Date:  1997-05-22       Impact factor: 2.778

9.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo.

Authors:  P H Van der Graaf; E A Van Schaick; S A Visser; H J De Greef; A P Ijzerman; M Danhof
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

Review 10.  Lessons from rat models of hypertension: from Goldblatt to genetic engineering.

Authors:  Y M Pinto; M Paul; D Ganten
Journal:  Cardiovasc Res       Date:  1998-07       Impact factor: 10.787

View more
  7 in total

1.  Semi-mechanistic modelling platform to assess cardiac contractility and haemodynamics in preclinical cardiovascular safety profiling of new molecular entities.

Authors:  Raja Venkatasubramanian; Teresa A Collins; Lawrence J Lesko; Jerome T Mettetal; Mirjam N Trame
Journal:  Br J Pharmacol       Date:  2020-06-18       Impact factor: 8.739

2.  Inter-study variability of preclinical in vivo safety studies and translational exposure-QTc relationships--a PKPD meta-analysis.

Authors:  V Gotta; F Cools; K van Ammel; D J Gallacher; S A G Visser; F Sannajust; P Morissette; M Danhof; P H van der Graaf
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

3.  Quantitative pharmacokinetic-pharmacodynamic modelling of baclofen-mediated cardiovascular effects using BP and heart rate in rats.

Authors:  Harriet Kamendi; Herbert Barthlow; David Lengel; Marie-Eve Beaudoin; Debra Snow; Jerome T Mettetal; Russell A Bialecki
Journal:  Br J Pharmacol       Date:  2016-08-25       Impact factor: 8.739

4.  Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.

Authors:  N Snelder; B A Ploeger; O Luttringer; D F Rigel; F Fu; M Beil; D R Stanski; M Danhof
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

5.  The 24 h pattern of arterial pressure in mice is determined mainly by heart rate-driven variation in cardiac output.

Authors:  Theodore W Kurtz; Heidi L Lujan; Stephen E DiCarlo
Journal:  Physiol Rep       Date:  2014-11-26

6.  A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variables.

Authors:  Yu Fu; Hadi Taghvafard; Medhat M Said; Eric I Rossman; Teresa A Collins; Stéphanie Billiald-Desquand; Derek Leishman; Piet H van der Graaf; J G Coen van Hasselt; Nelleke Snelder
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-03-18

Review 7.  Modeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety Assessment.

Authors:  T A Collins; L Bergenholm; T Abdulla; Jwt Yates; N Evans; M J Chappell; J T Mettetal
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.